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Some pharmacologic actions of yohimbine and 
chlorpromazine in man 
Yohimbine was found to produce psychic and autonomic changes resembling anxiety in man. 
Chlorpromazine, reserpine, amobarbital and atropine modified the response to yohimbine. 
Both reserpine and amobarbital reduced the drug's psychic and autonomic effect, while 
atropine decreased the pressor response to yohimbine. Chlorpromazine acted paradoxically, 
potentiating both psychic and autonomic responses. 
It is suggested that in the dose used in this study, yohimbine does not have its usual 
alpha-adrenergic blocking action but may produce these reactions by central stimulation of 
the autonomic nervous system. 
Charles G. Ingram, M.B., Ch.B., D.A. Ypsilanti, Mich. 
University of Michigan and Ypsilanti State Hospital 
Yohimbine partially blocks the pressor 
response to sympathetiC nerve stimulation 
and produces vasomotor reversal to injected 
epinephrine,"' 17, 18, 20 and it is now classi-
fied as an alpha-adrenergic blocking agent 
largely on the basis of these pharmacologic 
effects in studies on animals. Recently, 
Holmberg and Gershon7 reported that 
small doses had a stimulant action in man 
resulting in psychic and autonomic changes 
commonly associated with the subjective 
experience of anxiety. The degree of auto-
nomic response was reported to correlate 
highly with the subject's initial anxiety 
level. On the basis of this report, it seemed 
that the yohimbine response could pro-
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vide a useful method for testing the effec-
tiveness of drugs used to control anxiety. 
The present study was therefore under-
taken to determine the effect of several 
known psychoactive drugs upon the auto-
nomic and psychic responses produced by 
yohimbine and to attempt a fuller under-
standing of its mechanism and site of 
action. 
Method 
The subjects were 25 patients, 13 schizo-
phrenics, 8 alcoholics, and 4 sexual devi-
ates, between the ages of 18 and 40 years. 
Five of the schizophrenics were diagnosed 
as paranoid and the other 8 were of the 
chronic undifferentiated type. All tests 
were carried out with the subjects lying 
supine in a polygraph test room. Blood 
pressure, electrocardiogram, respiration, 
skin resistance, skin temperature, and bal-
listocardiogram measurements were re-
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corded. A heparinized Heyman-Olafson 
needle was inserted into a suitable vein 
while electrodes were applied to the sub-
ject. The needle, having a rubber dia-
phragm, allows administration of repeated, 
accurately timed injections without disturb-
ing the subject. A 5 minute baseline 
recording was taken after an acclimatiza-
tion period, then 2 m!. of saline was 
injected over a 1 minute period. After a 5 
minute recovery period, yohimbine hydro-
chloride in a dose of 0.1 mg. per kilogram 
of body weight per minute was adminis-
tered intravenously over a 5 minute period. 
The dose was chosen because it had previ-
ously been shown to produce a stimulant 
action.7 Recordings were continued for at 
least 20 minutes after the injection. A 
similar injection and recording routine was 
used in ~esting the subject's response to 
intravenous epinephrine and norepineph-
rine. L-Epinephrine bitartarate and L-nor-
epinephrine bitartarate were infused in a 
dose of 0.2 fLg per kilogram of body weight 
per minute over a period of 6 minutes. 
After the initial test establishing the re-
sponse to yohimbine, epinephrine, and 
norepinephrine, the subjects were given 
chlorpromazine, reserpine, sodium amy tal, 
or atropine sulfate and then retested with 
yohimbine, epinephrine, and norepineph-
rine. Twenty of the subjects were given 
chlorpromazine (10 mg. per kilogram per 
day) orally for at least 4 weeks and then 
retested while still receiving it. Ten patients 
were retested with yohimbine, epinephrine, 
and norepinephrine after receiving oral 
doses of 0.05 mg. per kilogram per day of 
reserpine for 3 weeks. Amobarbital sodium 
(5 mg. per kilogram) was given intrave-
nously to 8 subjects just prior to retesting. 
Six patients received atropine sulfate (0.04 
mg. per kilogram) by intravenous injection 
immediately prior to retest with yohimbine. 
Results 
Saline injection. None of the patients 
showed either subjective or autonomic re-




Yohimbine response prior to drug treat-
ment. The intravenous injection of yohim-
bine produced psychic and autonomic 
effects, as previously reported! Most com-
monly, the initial signs were facial Hush 
and increased heart rate. These were 
quickly followed by perspiration, lacrima-
tion, salivation, dilation of the pupils, in-
creased rate and depth of respiration, and 
elevation of blood pressure. The rise in 
blood pressure usually occurred 3 minutes 
after the beginning of the injection and 
remained elevated for 30 minutes or more 
after the injection was completed. The 
magnitude of the pressor response varied 
considerably from patient to patient but 
was present in all cases. The magnitude of 
this increase in blood pressure correlated 
positively, at a statistically significant level, 
with the baseline anxiety rating of the pa-
tient as rated by six independent raters. 
Both the systolic and diastolic blood pres-
sures increased with the injection of yohim-
bine. The mean rise in systolic blood pres-
sure for the 25 subjects in this study was 
18.5 mm. Hg (S.E. ± 0.4). The mean rise 
in diastolic blood pressure was 6.1 mm. Hg 
(S.E. ± 1.2). Skin temperature always rose, 
and skin resistance dropped. Those sub-
jects who reacted most strongly to yohim-
bine showed generalized tremors. 
The psychic changes observed were rest-
lessness, irritability, a tense facial expres-
sion, obvious anxiety, and a marked reluc-
tance to repeat the drug test. It was not 
possible to have several observers rate the 
anxiety induced by the yohimbine, but it 
was always much more marked than that 
seen during the injection of other auto-
nomic drugs. A few subjects complained 
of nausea and urgency of micturition and 
defecation. No differences in response to 
yohimbine were observed between the dif-
ferent diagnostic groups used in the study. 
Response to epinephrine and norepineph-
rine. There was a pressor response to both 
epinephrine and norepinephrine in the dos-
age used (0.2 fLg per kilogram). The mean 
rise in systolic blood pressure with epi-
nephrine was 21.7 mm. Hg (S.E. ± 2.9) 
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and was 21.3 mm. Hg (S.E. ± 4.1) with 
norepinephrine. Apart from a slight throb-
bing in the neck no subjective sensations 
were reported after norepinephrine. During 
the injection of epinephrine, only 3 of the 
20 patients reported feeling anxious and 15 
said they noticed somatic sensations similar 
to those felt when they were excited or 
anxious, but that they did not feel anxious. 
Responses to test drugs after chlorpro-
mazine medication. The yohimbine re-
sponse was found to be greatly exaggerated 
in patients who had received chlorproma-
zine for 4 weeks and were still taking the 
drug when tested. Whereas some patients 
responded to yohimbine with only a small 
increase in blood pressure or slight anxiety 
prior to chlorpromazine medication, all 
subjects now showed an obvious anxiety 
reaction and a marked potentiation of the 
autonomic effects after it. The pressor re-
sponse to yohimbine especially was mark-
edly increased. The mean systolic blood 
pressure rise in these 20 subjects was 17.1 
mm. Hg before and 41.9 mm. Hg after 
chlorpromazine medication. Similarly, the 
increase in diastolic blood pressure with 
yohimbine was greater after chlorproma-
zine than before. Both increases are sig-
nificant (p < 0.001). There was a slight 
but not statistically significant increase in 
heart rate with yohimbine after chlorpro-
mazine. Table I summarizes the changes in 
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the potentiated response. The pressor re-
sponse in a typical case is shown in Fig. 1. 
The difference in response to epineph-
rine and norepinephrine infusions before 
chlorpromazine medication was less marked 
than during it. The data are summarized in 
Tables II and Ill. The systolic blood pres-
sure response to epinephrine was con-
sistently depressed, the rise being 21.7 mm. 
Hg before and 14.7 mm. Hg after chlor-
promazine medication (p < 0.005). No 
significant changes in diastolic blood pres-
sure or heart rate were observed. The 
pressor response to norepinephrine was 
potentiated and prolonged in some cases 
but very little increased in others. The 
mean rise in systolic blood pressure was 
from 21.3 to 25.2 mm. Hg, and the mean 
rise in diastolic blood pressure was from 
3.9 to 6.5 mm. Hg. Both differences are 
statistically significant (p < 0.05). When 
potentiation of the norepinephrine pressor 
response by chlorpromazine did occur, it 
was always considerably less than that ob-
served with yohimbine. During the infusion 
of epinephrine and norepinephrine no al-
terations in the subjective symptoms were 
observed by the patient as a consequence 
of chlorpromazine premedication. 
Responses to test drugs after medication 
with reserpine. Ten patients were tested 
with yohimbine, epinephrine, and norepi-
nephrine before and after receiving reser-





Fig. 1. Systolic blood pressure re-
sponse to yohimbine before and dur-
ing administration of other drugs. 
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Table I. Mean systolic blood pressure, diastolic blood pressure, and heart rate 
response to yohimbine before and during chlorpromazine medication (20 sub;ects) 
""I"" ,,,,,,,,rom""'" t DUN,," """'prom""',,, Difference in 
Base line I Change Base line I Change change 
Determination ± S.E. ± S.E. ± S.E. ± S.E. ±S.E. p 
Systolie blood pressure 
(mm. Hg) 129.4 ± 2.6 17.1 ± 1.4 129.5± 3.4 41.9 ±4.6 24.8±4.6 0.001 
Diastolic blood pressure 
(mm. Hg) 85.9±2.2 4.7 ±0.7 89.1 ± 2.2 ILl ± 0.5 6.4 ± 0.5 0.001 
Heart rate 79.0±2.4 14.9 ± 1.2 83.1 ± 2.1 18.8 ± 1.3 3.9±2.7 Not signifi-
cant 
Table 11. Mean systolic blood pressure, diastolic blood pressure, and heart rate 





Determination ±S.E. ±S.E. 
--
Systolic blood pressure 
(mm. Hg) 119.7 ± 2.5 21.7 ± 2.9 
Diastolic blood pressure 
(mm. Hg) 90.1 ± 2.1 -4.1 ± 1.0 
Heart rate 77.3 ± 1.7 0.2± 1.6 
weeks). The psychic response to yohimbine 
was completely blocked by pretreatment 
with reserpine. The baseline systolic pres-
sure was reduced by 13.6 mm. Hg after 3 
weeks of treatment with reserpine; the 
systolic blood pressure rise induced by 
yohimbine was reduced from 20.1 to 12.3 
mm. Hg (p < 0.001) (see Table IV). 
The pressor response to epinephrine and 
norepinephrine was inconsistent from pa-
tient to patient among the 10 subjects 
tested, and no Significant over-all change 
from their pressor responses before being 
given reserpine was observed. 
Response to test drugs after intravenous 
injection of amobarbital sodium. Eight pa-
tients were tested with yohimbine and re-
tested a few days later after an intravenous 
injection of sodium amy tal (5 mg. per kilo-
gram) just prior to retesting. After amo-




±S.E. ±S.E. ±S.E. p 
117.7±2.7 14.7±2.7 -7.0 ±2.2 0.005 
86.2 ±2.5 -5.0± 0.9 0.9 ± 1.1 Not signifi-
cant 
81.5± 2.3 -0.3 ± 1.7 0.5±4.8 Not signifi-
cant 
barbital, all the subjects went into a light 
sleep and 5 remained asleep during the 
subsequent injection of yohimbine. The 
baseline systolic blood pressure was some-
what reduced following the injection of 
sodium amy tal. Yohimbine given 10 min-
utes later produced a mean pressor re-
sponse of 7.8 mm. Hg, as compared with 
16.2 mm. Hg before amobarbital( p < 
0.05). None of the other autonomic effects 
of yohimbine were observed. The usual 
increase in heart rate after the injection of 
yohimbine was abolished by amobarbital 
(Table V). 
Response to yohimbine after atropine 
sulfate. Six subjects were given atropine 
sulfate (0.04 mg. per kilogram) by intrave-
nous injection. This treatment also con-
siderably reduced the pressor response to 
yohimbine from a rise of 23.4 to one of 5.4 
Volume 3 
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mm. Hg (p < 0.005) (Table IV). How-
ever, other autonomic responses were not 
significantly altered, and the psychic ef-
fects seemed only partially depressed. 
Discussion 
The literature on yohimbine is limited to 
studies in animals and has dealt only with 
its action in blocking the effects of epi-
nephrine and sympathetic stimulation. The 
dose required to ensure block of sympa-
thetic stimulation is reported to be 2 to 5 
times as great as that required to block 
responses to injected epinephrine. This 
dosage range is much greater than that 
used in the present study in man. Jang8 
describes the use of low concentrations of 
yohimbine in experiments with the perfused 
rabbit's ear to sensitize the ear to epineph-
rine, but there appears to be no report in 
the literature of small doses causing 
psychic stimulation or sympathomimetic 
effects. Koppanyill states that yohimbine 
does not have an initial pressor effect like 
ergotamine when administered to dogs. He 
was, however, using large doses. 
In his review of adrenergic blocking 
agents, Nickerson17 lists some central, but 
mainly depressant, actions of yohimbine. 
One possibly significant factor is that all 
the animal investigations reported with this 
drug have been carried out under general 
anesthesia. The present study demonstrates 
that amobarbital blocks the psychic and 
autonomic stimulant effects of yohimbine, 
and it is likely therefore that the failure to 
observe a pressor response has been due to 
the use of anesthetized preparations. 
In his studies of the subjective effects 
produced by the injection of autonomic 
drugs in psychotic and psychoneurotic pa-
tients, Lindemann12, 13 first demon~trated 
that the epinephrine and methacholine ef-
fects were not related to the type of the 
disease but to the adjustment prevailing in 
the patient. As previously stated, no corre-
lation was found in this study between 
either the degree of induced anxiety or the 
magnitude of the pressor response and the 
diagnostic category. The intensity of anxi-
ety induced by yohimbine did correlate 
positively with the preinjection anxiety 
level, as did the magnitude of the pressor 
response. Lindemann12 also demonstrated 
the variability of subjective responses on 
repeated testing of the same subject. In the 
few patients who were subjected to re-
peated tests with yohimbine, no great vari-
ability was observed. Certainly, no change 
in response seen on repeated testing was 
ever as great as the change induced by 
prior medication with the drugs used in 
this study. 
The administration of reserpine for 3 
weeks markedly inhibits pressor responses 
to yohimbine, which may indicate that only 
a small part of the normal pressor response 
is due to direct stimulation of peripheral 
adrenergic receptors and that the normal 
pressor response is mediated by catechol-
Table Ill. Mean systolic blood pressure, diastolic blood pressure, and heart rate 
response to norepinephrine before and during chlorpromazine medication (20 subjects) 
Before chlorpromazine During chlorpromazine Difference 
Base line I Change Base line I Change in change 
Determination ±S.E. ±S.E. ± S.E. ±S.E. ±S.E. p 
----------
Systolic blood pressure 
(mm. Hg) 121.4 ± 2.3 21.3±4.1 119.7 ±2.1 25.2±4.2 3.9±2.0 0.05 
Diastolic blood pressure 
(mm. Hg) 90.4 ± 2.2 3.9 ± 0.4 88.3±2.5 -6.5± 0.8 2.6 ± 1.1 0.05 
Heart rate 71.1 ± 1.4 -19.1 ± 1.8 78.8±2.5 -20.9 ± 1.6 -1.8 ± 2.0 Not signifi-
cant 
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Table IV. Mean systolic blood pressure response to yohimbine before and after 
reserpine and atropine 
Before drug I After drug Difference 
Number Base line Change Base line Change in change 
of ± S.E. ± S.E. ± S.E. ± S.E. ±S.E. 
Drug subiects (mm. Hg) (mm. Hg) (mm. Hg) (mm. Hg) (mm. Hg) p 
Reserpine 0.05 mg. 
per Kg. per day for 
3 weeks 10 124.7 ± 6.0 20.1 ± 2.4 llU ± 6.4 7.8± 2.1 -12.3 ± 1.6 0.001 
Atropine sulfate 6 133.1 ± 4.3 23.4 ± 6.9 120.2 ± 4.7 5.4 ± 4.7 -18.0±3.9 0.005 
amines which are depleted after reserpine 
premedication. 
The observation that amobarbital blocks 
the pressor response to yohimbine suggests 
a central mechanism. The view is strength-
ened by the fact that psychic effects in-
duced by this drug do not seem to be due 
to its peripheral autonomic effects. Some 
patients who had a moderate pressor re-
sponse after yohimbine showed marked 
anxiety but after an epinephrine-induced 
pressor response of similar magnitude gave 
no indication of anxiety. 
Other adrenergic blocking agents are 
known to have central stimulating effects 
in low dosage, and the production of hyper-
tension by benzodioxanes has been reported 
in unanesthetized animals by Bing and 
Thomas2 and in man by Goldenberg, Sny-
der, and Aranow. 4 Handowsky6 proposes 
that this pressor response to the benzodiox-
anes is mediated through central stimula-
tion. 
Atropine depression of the pressor re-
sponse to yohimbine would seem to support 
the view that muscarinic synapses exist in 
the descending vasomotor pathways from 
the mesencephalon.14 The finding that mus-
carinic responses to yohimbine such as 
sweating and salivation were not signifi-
cantly altered suggests that the dose of 
atropine was too small. 
In every subject, chlorpromazine poten-
tiated yohimbine's autonomic and psychic 
effect (p < 0.001). Potentiation of the 
pressor response of both norepinephrine 
and yohimbine is somewhat surprising in 
view of the evidence for the alpha-ad-
renergic blocking action of chlorpromazine 
initially described by Kopera and Armi-
tage,I° who demonstrated that it blocked 
the local vasoconstrictor effects of L-epi-
nephrine. Courvoisier and colleagues3 and 
Jourdan, Duch€me-Marullaz, and Boissier9 
showed that it reduced or reversed the 
pressor responses to epinephrine. Martin 
and Riehl/5 however, demonstrated that 
chlorpromazine could enhance and prolong 
Table V. Mean systolic blood pressure, diastolic blood pressure, and heart rate 
before and after amobarbital sodium 
Before drug After drug Difference in 
Base line 
I 
Change Base line 
I 
Change change 
Determination ±S.E. ±S.E. ±S.E. ±S.E. ±S.E. p 
Systolic blood pressure 
(mm. Hg) 120.1 ±4.6 16.2 ± 3.8 116.1 ± 4.4 7.8± 3.7 -8.2± 3.2 0.05 
Diastolic blood pressure 
(mm. Hg) 89.1 ± 1.9 5.1 ± 0.9 86.3±2.3 3.7± 0.5 -1.4±0.7 0.05 
Heart rate 72.4 ± 1.7 12.9 ± 2.0 76.7 ± 1.7 2.1 ± 2.1 -10.8±2.2 0.001 
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the pressor response evoked by levarterenol 
in cats which had undergone spinal vagot-
omy. After further investigation of this 
finding, Martin, Riehl, and Unna16 proposed 
that chlorpromazine had two dissociated 
actions: (1) block of the adrenergic recep-
tors and (2) depression of some deactivat-
ing process. 
Among the possible mechanisms of this 
potentiation are the depression of normal 
cardiovascular buffer mechanisms and sen-
sitizationof the central autonomic system. 
It is interesting to note that imipramine, a 
structural analogue of chlorpromazine, also 
potentiates the psychic and autonomic ef-
fects of yohimbine.7 Although the mode of 
action of imipramine is still uncertain, 
Sigg19 proposed sensitization of central ad-
renergic receptors as one of its actions. 
On the basis of (1) the depreSSion of 
the yohimbine response by the previous 
administration of amobarbital and (2) by 
analogy with the central action of the 
benzodioxanes, it is suggested that yohim-
bine may produce its pressor and anxiety 
response by action through the central au-
tonomic system. 
Conclusion 
In a dose of 0.1 mg. per kilogram per 
minute for 5 minutes, yohimbine was found 
to produce psychic and autonomic changes 
resembling anxiety. 
Chlorpromazine, reserpine, amobarbital, 
and atropine modified the response to 
yohimbine. Both reserpine and amobarbital 
reduced the drug's psychic and autonomic 
effects, while atropine decreased the pres-
sor response to yohimbine. ChlorpromaZine 
acted paradoXically, potentiating both psy-
chic and autonomic responses. 
The results of this study and those of 
other workers suggest that in the dose used 
in this study, yohimbine does not exert its 
usual alpha-adrenergic blocking action but 
produces the reactions reported by central 
stimulation of the autonomic system. 
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